Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-07-02

Clinical Trial Update: Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating retinal pigment epithelium autoimmunity in age-related macular degeneration has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Lawrence S. Morse, MD | Conditions: Age Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2017-07-02